Florida cannabis laws

Florida authorized medical cannabis in 2016 through a constitutional amendment, but it remains one of the largest states in the nation without adult-use legalization. A ballot measure to permit recreational sales, Amendment 3, failed in November 2024 after falling short of the 60 percent supermajority required for constitutional amendments in the state. The vote was unusually contentious, with the state's governor and Republican legislative leaders deploying significant opposition messaging, while much of the campaign funding in favor came from Trulieve, the state's dominant vertically integrated operator. The failure left Florida as the most populous medical-only cannabis jurisdiction in the country and ensured that the state's legal market would remain restricted to patients with qualifying conditions for the foreseeable future.

The reclassification of cannabis to Schedule III under the Controlled Substances Act in early 2026 did not alter Florida's state-level legal framework, which had already decriminalized low-level possession in some localities and maintained a tightly regulated medical program. However, the federal shift has created friction in areas such as banking access, tax treatment under Section 280E, and firearm ownership rules for medical patients. Florida's regulatory structure remains among the most restrictive in the nation for a state with an established medical program, with no homegrow provision, limited qualifying conditions compared to other states, and strict vertical integration requirements that have consolidated market power among a handful of large operators.

Medical Cannabis Program and Patient Access

Florida's medical cannabis program operates under the 2016 constitutional amendment and subsequent enabling legislation passed in 2017. Patients must obtain a recommendation from a state-licensed physician who has completed a required cannabis education course, and they must be diagnosed with one of the qualifying conditions. These include cancer, epilepsy, glaucoma, HIV/AIDS, post-traumatic stress disorder, amyotrophic lateral sclerosis, Crohn's disease, Parkinson's disease, multiple sclerosis, and any terminal condition. Physicians also have discretion to certify patients for conditions of like, kind, or class to those enumerated, or for chronic nonmalignant pain, though pain certifications require additional documentation and review. As of mid-2026, Florida has approximately 875,000 active registered medical cannabis patients, making it the third-largest program by enrollment in the United States.

Possession limits for patients are set at a 70-day supply of cannabis products, with the specific amount determined by the certifying physician. Most physicians authorize a maximum of 2.5 ounces of smokable flower per 35-day period, which translates to five ounces over 70 days. THC concentrates, edibles, tinctures, and topicals are also permitted, with milligram limits that vary depending on the product form. Patients must purchase cannabis from one of the state-licensed Medical Marijuana Treatment Centers, which are vertically integrated entities required to handle cultivation, processing, and retail under a single license. This vertical integration model was designed to ensure seed-to-sale tracking but has also limited the diversity of market participants. As of 2026, there are 25 licensed operators in Florida, though the top five control more than 75 percent of total sales, with Trulieve alone accounting for roughly half the market.

Dispensaries are clustered in urban areas, and rural patients often face significant travel distances to access products. The state does allow delivery, which has expanded access somewhat, though delivery services are not universally offered by all operators. Florida's medical program does not recognize out-of-state medical cannabis cards, meaning visitors cannot legally purchase or possess cannabis in the state even if they hold valid certifications elsewhere.

Possession, Public Consumption, and Enforcement

Possession of cannabis without a valid medical card remains illegal in Florida. For non-patients, possession of 20 grams or less is a first-degree misdemeanor, punishable by up to one year in jail and a $1,000 fine. Possession of more than 20 grams is a felony, with penalties escalating based on quantity. Some municipalities, including Miami-Dade County, Orlando, and Tampa, have enacted civil citation programs that allow law enforcement to issue fines instead of criminal charges for small amounts, but these programs are not statewide and enforcement varies by jurisdiction. Arrest data from 2025 showed that Florida law enforcement made approximately 18,000 arrests for cannabis possession, a figure that has declined from prior years but remains substantial compared to states with broader decriminalization policies.

Public consumption of cannabis is prohibited for both medical patients and non-patients. Smoking or vaping cannabis in public places, including parks, sidewalks, and vehicles, is illegal and can result in fines or arrest. Medical patients are permitted to consume cannabis in private residences or in designated areas approved by property owners. The lack of public consumption venues or social-use licenses means that patients without access to private property face practical barriers to legal use.

Homegrow and Cultivation Restrictions

Florida does not permit homegrow for medical patients or any other residents. The 2016 constitutional amendment and subsequent legislation explicitly prohibit personal cultivation, a provision that has drawn sustained criticism from patient advocates and reform groups. Efforts to introduce homegrow legislation in the state legislature have repeatedly stalled, with opposition coming from both lawmakers concerned about diversion and from licensed operators who benefit from the captive market. The failed 2024 adult-use ballot measure also did not include a homegrow provision, which some analysts believe contributed to its inability to mobilize a broader coalition of reform advocates. As it stands, Florida patients and consumers have no legal pathway to grow cannabis for personal use, making it one of the few medical states with an outright cultivation ban.

Employer Protections and Workplace Rights

Florida law does not provide employment protections for medical cannabis patients. Employers retain the right to maintain drug-free workplace policies, conduct pre-employment and random drug testing, and terminate or refuse to hire individuals who test positive for THC, even if they are registered patients using cannabis in compliance with state law. Several court cases in Florida have affirmed that the medical cannabis program does not create a private right of action against employers for adverse employment decisions based on lawful cannabis use. This leaves patients in safety-sensitive industries, such as transportation, healthcare, and construction, in a precarious position. The Schedule III reclassification has not changed this dynamic at the state level, though federal contractors and employers subject to Department of Transportation regulations continue to face additional constraints.

Cross-Border and Federal Complications

Transporting cannabis across state lines remains a federal felony, and Florida's borders with Georgia and Alabama, where cannabis remains fully illegal, create enforcement risks for travelers. Law enforcement in border counties conducts traffic stops and interdiction operations, and out-of-state vehicles are sometimes targeted. Florida patients cannot legally bring their medicine on commercial flights, even for intrastate travel, due to federal aviation security rules. Firearm ownership presents another complication. Federal law prohibits cannabis users from purchasing or possessing firearms, and Florida patients who attempt to buy guns must answer a federal background check form that asks about unlawful controlled substance use. The Schedule III change has not resolved this conflict, and patients remain at risk of federal prosecution if they provide false answers on ATF Form 4473.

Equity, Social Justice, and Expungement

Florida's medical cannabis program includes no equity provisions, social equity licenses, or targeted support for communities disproportionately affected by cannabis prohibition. The licensing structure has favored well-capitalized applicants, and the limited number of licenses has prevented new entrants from gaining a foothold. Expungement of prior cannabis convictions is available through a case-by-case petition process, but Florida does not offer automatic expungement or broad relief for past offenses. Advocates have criticized the state's failure to address the harms of prohibition even as it built a lucrative regulated market. Legislative proposals to create expungement pathways and equity licensing have not advanced, and the political environment remains challenging for reform measures that do not have strong bipartisan support.

Market Structure and Industry Trends

Florida's cannabis market generated approximately $2.1 billion in sales in 2025, making it one of the largest medical-only markets in the world. The vertical integration requirement has concentrated market power among a small number of multi-state operators and Florida-based firms. Trulieve operates more than 200 dispensaries statewide, while Curaleaf, Surterra Wellness, and AYR Wellness also maintain significant footprints. Smaller operators struggle to compete on price and distribution scale, and there is minimal craft or boutique presence in the market. Product pricing has remained relatively stable, with eighths of flower typically ranging from $30 to $55 depending on quality and brand. Concentrates and vapes are priced higher on a per-milligram basis, and discounts for seniors, veterans, and patients receiving public assistance are common.

The illicit market remains substantial in Florida, particularly in areas with limited dispensary access and among consumers unwilling to pay for medical certification. Hemp-derived THC products, including delta-8 and delta-9 edibles sold in convenience stores and online, have also captured market share since federal hemp legalization in 2018. These products occupy a legal gray area, as Florida has not enacted explicit restrictions on intoxicating hemp cannabinoids, though periodic enforcement actions and regulatory proposals have created uncertainty. The Schedule III change has not directly impacted hemp-derived products, which remain governed by separate federal and state hemp statutes.

Looking ahead, the prospects for adult-use legalization in Florida are uncertain. Another ballot initiative could emerge in 2026 or 2028, but organizers would need to secure funding, gather hundreds of thousands of signatures, and overcome coordinated opposition from state officials. Legislative action is unlikely given the Republican supermajorities in both chambers and the governor's stated opposition to recreational cannabis. For the time being, Florida's cannabis landscape will remain defined by a large but restricted medical market, persistent criminalization of non-patients, and ongoing tension between state licensees, illicit operators, and the burgeoning hemp sector.